All Trials

A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and measurable, unresectable stage III/IV NRAS-mutant melanoma or other advanced solid tumors refractory to, intolerant of, or declining standard therapy receive oral RLY-8161, a selective NRAS inhibitor designed to suppress RAS–MAPK signaling while sparing KRAS and HRAS. Dose escalation is followed by expansion at the selected recommended dose(s).

ClinicalTrials.gov ID: NCT07584226

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS02 in Participants With EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with EGFR-mutated locally advanced or metastatic NSCLC, measurable disease, and ECOG 0–1 receive oral ANS02 monotherapy. ANS02 is a fourth-generation, mutant-selective EGFR tyrosine kinase inhibitor targeting activating and resistance mutations, including T790M and C797S-containing mutants, while relatively sparing wild-type EGFR.

ClinicalTrials.gov ID: NCT07538804

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adult women with relapsed/refractory ovarian carcinoma or carcinosarcoma after standard therapies receive single-agent NTB-928, including those with platinum-resistant/refractory disease or platinum-sensitive disease ineligible for further platinum. NTB-928 is a fully human bispecific T-cell engager targeting FRα/FOLR1 on tumor cells and CD3 on T cells to promote immune-mediated tumor killing.

ClinicalTrials.gov ID: NCT07690189

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-resistant epithelial ovarian, primary peritoneal, or fallopian-tube cancer receive autologous GB-5267, an IL-18–secreting CAR T-cell therapy targeting membrane-bound MUC16. Dose escalation uses intravenous administration, followed by expansion evaluating combined intravenous and intraperitoneal delivery.

ClinicalTrials.gov ID: NCT07489287

Phase 1/2 Study Of IL15-Transduced, TGFBR2 KO, TROP2 CAR- Engineered Cord Blood-Derived NK Cells Administered Intraperitoneally And Intravenously In Combination With Oral Belzutifan For The Management Of Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable recurrent, unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma or ampullary carcinoma progressing after FOLFIRINOX or gemcitabine-based therapy receive intraperitoneal and intravenous allogeneic cord-blood CAR-NK cells plus oral belzutifan. The CAR-NK cells are engineered with a TROP2-directed CAR (target requires protocol confirmation), IL-15 expression, and TGFBR2 knockout; belzutifan inhibits HIF-2α.

ClinicalTrials.gov ID: NCT07377526

BActinium-1: A Phase 1b, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Intravenous Administration of B7-H3 Radiopharmaceutical ([225Ac]Ac-AKY-2519) in Metastatic Castration-Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressive mCRPC, ECOG 0–1, and limited prior AR pathway inhibitor/taxane therapy are enrolled in cohorts based on prior 177Lu-PSMA-617 exposure. Patients receive IV [225Ac]Ac-AKY-2519, a B7-H3/CD276-targeted miniprotein radiopharmaceutical that delivers alpha radiation after tumor internalization, with optional [64Cu]Cu-AKY-2519 imaging for biodistribution and dosimetry.

ClinicalTrials.gov ID: NCT07581184

Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-guided T Cell-engaging Antibody That Targets STEAP2, in Adult Participants With Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressive metastatic castration-resistant prostate adenocarcinoma or neuroendocrine-differentiated prostate cancer after androgen-receptor pathway inhibition and other specified prior therapies receive AZD8359 at escalating or selected dose levels and schedules. AZD8359 is a STEAP2-targeted, CD8-biased T-cell engager designed to direct cytotoxic CD8+ T cells against STEAP2-expressing prostate cancer cells.

ClinicalTrials.gov ID: NCT07529717

A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic prostate adenocarcinoma progressing during or after their most recent therapy, with ECOG 0–1 and ongoing androgen deprivation, receive single-agent GDC-1261 in dose-escalation or expansion cohorts. GDC-1261 is an investigational anticancer agent with an undisclosed target and mechanism of action.

ClinicalTrials.gov ID: NCT07567846

A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.

ClinicalTrials.gov ID: NCT05519293

A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients With Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: The trial involves patients who are postmenopausal women with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer, focusing on the safety and efficacy of EP0062 (vosilasarm), a selective androgen receptor modulator. Participants must have previously treated, inactive cancer and meet specific cardiac and medication criteria.

ClinicalTrials.gov ID: NCT05573126